Table 3.
Two patients who failed to respond to sofosbuvir plus ledipasvir treatment.
| No. | Age/Gender | Previous Treatment Response | GT | Cirrhosis/HCC | Efficacies | Adherence >80% | NS5A-L31 | NS5A-Y93 | NS5B-S282 |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 66/Male | PegIFN/RBV null response | 1b | Yes/+ | Relapse (post 4 w) | Yes | M | M | W |
| 2 | 58/Male | IFN null response | 1b | Yes/− | Relapse (post 8 w) | Yes | M | W | W |
PegIFN/RBV, peginterferon plus ribavirin; GT, genotype; HCC, previous curative treatment of hepatocellular carcinoma; M, mutation; and W, wild-type. Resistance-associated variants (NS5A-L31 and Y93 and NS5B-S282) after treatment-relapse were determined by direct-sequence methods. Patient no. 2 took a proton pump inhibitor during treatment.